Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BAY 12 9566

Latest Information Update: 20 Nov 2000

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Developer Bayer; National Cancer Institute (Canada)
  • Class Antineoplastics; Butyric acids; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Non-small cell lung cancer; Osteoarthritis; Ovarian cancer; Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 20 Nov 2000 Results of a phase III study in patients with ovarian cancer have been added to the adverse events and Cancer therapeutic trials section
  • 23 May 2000 BAY 129566 is now called tanomastat (INN)
  • 07 Mar 2000 A clinical study has been added to the adverse events, pharmacokinetics and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top